
Diagnostics, Год журнала: 2025, Номер 15(7), С. 937 - 937
Опубликована: Апрель 6, 2025
Background/Objectives: Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel biomarker for liver fibrosis, and its prognostic role has never been explored in coronavirus disease 2019 (COVID-19). We compared the M2BPGi level simultaneously with age, severe/critical disease, sequential organ failure assessment (SOFA) score, National Early Warning Score 2 (NEWS2) total of 53 hospitalized patients COVID-19 (mild/moderate [n = 15] 38]). Methods: levels were measured using HISCL assay (Sysmex, Kobe, Japan) an HISCL-5000 analyzer (Sysmex), clinical outcomes analyzed according to variables, receiver operating characteristic (ROC) curve, Kaplan-Meier survival, Cox proportional hazards regression analyses. Results: differed significantly severity, 30-day mortality, 60-day mortality (p 0.045, 0.011, 0.002, respectively). In ROC curve analysis, M2BPGi, SOFA NEWS2, except predicted (all p < 0.01). survival hazard ratios added each variable higher than that alone, was only independent factor mortality. Conclusions: This study demonstrated may be useful assessing severity patients. Combined conventional assessment, would provide objective valuable information prognosis prediction these critically ill Further studies are warranted extend utility other settings.
Язык: Английский